Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AnaptysBio Inc (ANAB)
NASDAQ:ANAB
Holding ANAB?
Track your performance easily
ANAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$13.36 - $41.31
Previous Close$22.27
Volume744.60K
Average Volume (3M)391.18K
Market Cap
$677.65M
Enterprise Value$264.02M
Total Cash (Recent Filing)$430.12M
Total Debt (Recent Filing)$16.49M
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Feb 27, 2025EPS Estimate
-$1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.07
Shares Outstanding30,428,682
10 Day Avg. Volume458,245
30 Day Avg. Volume391,182
Standard Deviation0.21
R-Squared0.00337
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)7.33
Price to Sales (P/S)10.63
Price to Cash Flow (P/CF)-15.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.62
Enterprise Value/Gross Profit15.39
Enterprise Value/Ebitda-1.74
Forecast
1Y Price Target
$53.11Price Target Upside120.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
AnaptysBio News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceANAB reported a 3Q net loss of $32.9M, vs estimate of $43.6M and consensus at $46.1M.
Market OpportunitiesANB032 has a potential market opportunity of about $2 billion, assuming use in dupi experienced patients.
Pipeline DevelopmentsANAB's early pipeline offers future optionality with upcoming data and potential catalysts.
Bears Say
Discontinued DrugThe discontinuation of LY3361237 was due to the lack of efficacy, attributed to the drug's antagonistic properties and poor Fc engagement.
Low ConfidenceANB032 AD topline data are expected in Dec 2024; analysts maintain relatively low confidence.
Program TerminationShares are trading down -30% pre-market as LLY has removed peresolimab (its PD-1 agonist) from its pipeline chart.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ANAB FAQ
What was AnaptysBio Inc’s price range in the past 12 months?
AnaptysBio Inc lowest stock price was $13.36 and its highest was $41.31 in the past 12 months.
What is AnaptysBio Inc’s market cap?
Currently, no data Available
When is AnaptysBio Inc’s upcoming earnings report date?
AnaptysBio Inc’s upcoming earnings report date is Feb 27, 2025 which is in 93 days.
How were AnaptysBio Inc’s earnings last quarter?
AnaptysBio Inc released its earnings results on Nov 05, 2024. The company reported -$1.14 earnings per share for the quarter, beating the consensus estimate of -$1.647 by $0.507.
Is AnaptysBio Inc overvalued?
According to Wall Street analysts AnaptysBio Inc’s price is currently Undervalued.
Does AnaptysBio Inc pay dividends?
AnaptysBio Inc does not currently pay dividends.
What is AnaptysBio Inc’s EPS estimate?
AnaptysBio Inc’s EPS estimate is -$1.55.
How many shares outstanding does AnaptysBio Inc have?
AnaptysBio Inc has 30,428,682 shares outstanding.
What happened to AnaptysBio Inc’s price movement after its last earnings report?
AnaptysBio Inc reported an EPS of -$1.14 in its last earnings report, beating expectations of -$1.647. Following the earnings report the stock price went up 11.72%.
Which hedge fund is a major shareholder of AnaptysBio Inc?
Among the largest hedge funds holding AnaptysBio Inc’s share is Woodline Partners LP. It holds AnaptysBio Inc’s shares valued at 15M.
---
AnaptysBio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.11 (120.37% Upside)
$53.11 (120.37% Upside)
Blogger Sentiment
Bullish
ANAB Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 399.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 44.5%
Last 30 Days ▲ 44.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
56.83%
12-Months-Change
Fundamentals
Return on Equity
-161.81%
Trailing 12-Months
Asset Growth
1.25%
Trailing 12-Months
Company Description
AnaptysBio Inc
AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.
---
ANAB Stock 12 Month Forecast
Average Price Target
$53.11
▲(120.37% Upside)
Technical Analysis
Best Analysts Covering ANAB
1 Year
1 Year Success Rate
8/17 ratings generated profit
1 Year Average Return
-30.09%
reiterated a buy rating 14 days ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of -30.09% per trade.
---